Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority

The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients

IMPACT OF INTERLEUKIN-28 B (rs12979860) GENE POLYMORPHISM ON INTRAFAMILIAL TRANSMISSION OF HCV IN EGYPT.

INTERLEUKIN-6 (-597G/A) POLYMORPHISM IN EGYPTIAN HEPATITIS C-VIRUS INFECTED PATIENTS

ROLE OF SERUM INTERLEUKIN – 10 AND INTERLEUKIN -28B GENE POLYMORPHISMS IN PREDICTING TREATMENT RESPONSE OF HEPATITIS C PATIENTS

Interleukin 28 B genotype as a predictor of response to therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients

The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclat

Interleukin 28b Single Nucleotide Polymorphism (rs8099917) as a Predictive Factor of Response to Pegylated-IFN/Ribavirintherapy in Chronic HCV Patients

Interferon-Lambda 4 Gene Polymorphisms Predict Treatment Response in Egyptian HCV Genotype 4 Patients Exposed to Radiation

The Role of Interleukin-10 Gene Polymorphism in Egyptian Patients with Chronic Hepatitis C Virus